Literature DB >> 26698258

Visualization of nigrosomes-1 in 3T MR susceptibility weighted imaging and its absence in diagnosing Parkinson's disease.

P Gao1, P-Y Zhou, G Li, G-B Zhang, P-Q Wang, J-Z Liu, F Xu, F Yang, X-X Wu.   

Abstract

OBJECTIVE: To assess the imaging features of nigrosomes-1 in the substantia nigra through 3T MR susceptibility weighted imaging (SWI) and its disease-specific changes for the diagnosis of Parkinson's disease (PD). PATIENTS AND METHODS: A total of 116 subjects were included in this study and allocated into 3 groups: 54 patients diagnosed with PD were assigned to the PD group, 51 age- and sex-matched volunteers without PD served as the control N-PD group, and 11 clinically suspected PD patients were allocated to the undiagnosed (UD) group. All patients received 3.0T superconducting MRI scanning on xxx. The images were analyzed and compared to assess the ability of nigrosomes-1 signals to depict PD pathology.
RESULTS: The signals of nigrosomes-1 were strong, droplet-like or oval in shape, and were found in 49 patients from the N-PD group (96.08%), on both sides of the SN (47 cases) and unilaterally (2 cases). In contrast, these signals were absent in all 54 cases from the PD group, and were undetected in 7 out of 11 cases in the UD group, 7 cases without the "drop" and 1 case with narrow strips of hyperintensity were clinically proven to PD, 2 cases with the typical hyperintensity were clinically proven to Parkinson's plus syndrome, 2 cases with slightly wider strip of hyperintensity were less sensitive to the drug levodopa.
CONCLUSIONS: The absence of typical droplet-like or oval-shaped nigrosomes-1 signals in 3.0T MR SWI may prove useful in identifying PD and Parkinson's syndrome with high sensitivity and specificity.

Entities:  

Mesh:

Year:  2015        PMID: 26698258

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  9 in total

1.  Diagnostic performance of loss of nigral hyperintensity on susceptibility-weighted imaging in parkinsonism: an updated meta-analysis.

Authors:  Pyeong Hwa Kim; Da Hyun Lee; Chong Hyun Suh; Minjae Kim; Woo Hyun Shim; Sang Joon Kim
Journal:  Eur Radiol       Date:  2021-01-15       Impact factor: 5.315

2.  Imaging in Parkinson's disease.

Authors:  Richard J B Ellis; Malcolm Steiger
Journal:  Clin Med (Lond)       Date:  2017-07       Impact factor: 2.659

3.  Utility of Imaging of Nigrosome-1 on 3T MRI and Its Comparison with 18F-DOPA PET in the Diagnosis of Idiopathic Parkinson Disease and Atypical Parkinsonism.

Authors:  Heena Kathuria; Sahil Mehta; Chirag K Ahuja; Kamalesh Chakravarty; Sucharita Ray; Bhagwant Rai Mittal; Paramjeet Singh; Vivek Lal
Journal:  Mov Disord Clin Pract       Date:  2020-10-02

Review 4.  Brain MR Contribution to the Differential Diagnosis of Parkinsonian Syndromes: An Update.

Authors:  Giovanni Rizzo; Stefano Zanigni; Roberto De Blasi; Daniela Grasso; Davide Martino; Rodolfo Savica; Giancarlo Logroscino
Journal:  Parkinsons Dis       Date:  2016-09-28

5.  Fast 3 T nigral hyperintensity magnetic resonance imaging in Parkinson's disease.

Authors:  Gabriella Hernadi; David Pinter; Szilvia Anett Nagy; Gergely Orsi; Samuel Komoly; Jozsef Janszky; Norbert Kovacs; Gabor Perlaki
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

Review 6.  An Updated Overview of the Magnetic Resonance Imaging of Brain Iron in Movement Disorders.

Authors:  Nicola Tambasco; Pasquale Nigro; Andrea Chiappiniello; Federico Paolini Paoletti; Sara Scialpi; Simone Simoni; Pietro Chiarini; Lucilla Parnetti
Journal:  Behav Neurol       Date:  2022-02-24       Impact factor: 3.342

7.  Nigrosome 1 visibility at susceptibility weighted 7T MRI-A dependable diagnostic marker for Parkinson's disease or merely an inconsistent, age-dependent imaging finding?

Authors:  Carolin Gramsch; Iris Reuter; Oliver Kraff; Harald H Quick; Christian Tanislav; Florian Roessler; Cornelius Deuschl; Michael Forsting; Marc Schlamann
Journal:  PLoS One       Date:  2017-10-10       Impact factor: 3.240

Review 8.  Parkinson's Disease: Available Clinical and Promising Omics Tests for Diagnostics, Disease Risk Assessment, and Pharmacotherapy Personalization.

Authors:  Oxana P Trifonova; Dmitri L Maslov; Elena E Balashova; Guzel R Urazgildeeva; Denis A Abaimov; Ekaterina Yu Fedotova; Vsevolod V Poleschuk; Sergey N Illarioshkin; Petr G Lokhov
Journal:  Diagnostics (Basel)       Date:  2020-05-25

9.  Protocol of a single group prospective observational study on the diagnostic value of 3T susceptibility weighted MRI of nigrosome-1 in patients with parkinsonian symptoms: the N3iPD study (nigrosomal iron imaging in Parkinson's disease).

Authors:  Stefan T Schwarz; Yue Xing; Saadnah Naidu; Jim Birchall; Rob Skelly; Alan Perkins; Jonathan Evans; Gill Sare; Antonio Martin-Bastida; Nin Bajaj; Penny Gowland; Paola Piccini; Dorothee P Auer
Journal:  BMJ Open       Date:  2017-12-14       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.